What we know about COVID-19 vaccination

DOI: https://doi.org/10.29296/25877305-2022-11-06
Issue: 
11
Year: 
2022

E. Mineeva(1, 2), Professor I. Demko(1, 2), MD; Professor E. Sobko, MD(1, 2),K. Shadrina(1)
1-Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
2-Territorial Clinical Hospital, Krasnoyarsk

Severe acute respiratory syndrome induced by SARS-CoV-2 (COVID-19) has caused its substantial morbidity and mortality in the world’s population. Long-term global practice shows that one of the most effective and dominant ways to prevent COVID-19 is to immunize the population with vaccines. The results of a coronavirus vaccination program published in different countries of the world demonstrate its high significance in the fight against the COVID-19 pandemic. There are now a number of registered coronavirus vaccines that have put through Phase III clinical trials and have shown their efficacy in combating this virus. Our literature review describes in detail most of the currently available COVID-19 vaccines, their design companies, design stages, the composition of vaccines, the results of clinical trials, the proven successful use of vaccines, as well as the inferred and identified side effects due to their use (both local and systemic reactions, as well as cases of more formidable and severe complications and their incidence). There is evidence that there is a need for large-scale coronavirus vaccination of the population. The attitude of the population in different countries to an active vaccination campaign and its satisfaction with currently available vaccines are detailed. Since the efficacy of COVID-19 vaccines attenuates over time, timely revaccination should also be considered. Vaccination is necessary, since the main value is a person’s health and life, so it is necessary to take measures for their preservation and the prevention of diseases.
Keywords: 
infectious diseases
COVID-19
vaccine
viral pneumonia
coronavirus infection
antibodies
immunity

References: 
  1. Vetter V., Denizer G., Friedland L. еt al. Understanding modern-day vaccines: What you need to know. Ann Med. 2018; 50: 110–20. DOI: 10.1080/07853890.2017.140703
  2. Gorenkov D., Khantimirova L., Shevtsov V. et al. An outbreak of a new infectious disease COVID-19: β-coronaviruses as a threat to global healthcare. BIOpreparations. Prevention, Diagnosis, Treatment. 2020; 20 (1): 6–20 (in Russ.). DOI: 10.30895/2221- 996X-2020-20-1-6-20
  3. Soldatov A.A., Avdeeva Z.I., Bondarev V.P. et al. Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic. BIOpreparations. Prevention, Diagnosis, Treatment. 2020; 20 (4): 228–44 (in Russ.). DOI: 10.30895/2221-996X-2020-20-4-228-244
  4. Smirnov I. COVID-19 (SARS-COV-2), from diagnosis to vaccine. Laboratoria i proizvodstvo. 2020; 3–4 (19): 108–17 (in Russ.). DOI: 10.32757/2619-0923.2020.3-4.13.108.117
  5. Kudlay D., Svistunov A. COVID-19 vaccines: an overview of different platforms. Bioengineering. 2022; 9 (2): 72. DOI: 10.3390/bioengineering9020072
  6. Knoll M.D., Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021; 397 (10369): 72–4. DOI: 10.1016/S0140-6736(20)32623-4
  7. Onishchenko G.G., Sizikova T.E., Lebedev V.N. et al. Analysis of Promising Approaches to COVID-19 Vaccine Development. BIOpreparations. Prevention, Diagnosis, Treatment. 2020; 20 (4): 216–27 (in Russ.). DOI: 10.30895/2221-996X-2020-20-4-216-227
  8. Petrov V.I., Gerasimenko A.S., Gorbatenko V.S. et al. Efficacy and safety of vaccines for the prevention of COVID-19. Medicinal Bulletin. 2021; 15 (2): 3–9 (in Russ.).
  9. Kozlov V.A., Tikhonova E.P., Savchenko A.A. et al. Klinicheskaya immunologiya. Prakticheskoe posobie dlya infektsionistov. Krasnoyarsk: Polikor, 2021; 563 c. (in Russ.). DOI: 10.17513/np.518
  10. Butsko DA. Comparative analysis of the vaccines "Sputnik V" and "Sputnik Lite" from the Gamalei National Research Center. Innovations and technologies in biomedicine. 2021; 378–81 (in Russ.).
  11. Frenck R.W., Klein N. P., Kitchin N. еt al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385: 239–50. DOI: 10.1056/NEJMoa2107456
  12. Masonbrink A.R., Hurley E. Advocating for Children During the COVID-19 School Closures. Pediatrics. 2020; 146 (3): e20201440. DOI: 10.1542/peds.2020-1440
  13. Polack F.P., Thomas S.J., Kitchin N. еt al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383: 2603–15. DOI: 10.1056/NEJMoa2034577
  14. Dooling K., Gargano J.W., Moulia D. еt al. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, September 2021. Weekly. 2021; 70 (38): 1344–8. DOI: 10.15585/mmwr.mm7038e2
  15. Male V. Are COVID-19 vaccines safe in pregnancy? Nat Rev Immunol. 2021; 21 (4): 200–1. DOI: 10.1038/s41577-021-00525-y
  16. Klein S.L., Creisher P.S., Burd I. COVID-19 vaccine testing in pregnant females is necessary. J Clin Investig. 2021; 131 (5): e147553. DOI: 10.1172/JCI147553.
  17. Denisenco A.S., Riss M.E., Kropachev I.G. et al. The first cases of coagulation disorders as complications after the introduction of the GAM-COVID-VAC vaccine (Sputnik V). Bulletin of the Novgorod State University. 2021; 3 (124): 61–4 (in Russ.). DOI: 10.34680/2076-8052.2021.3(124).61-64
  18. Petrov V.U., Plahuta T.G., Soskov G.I. Vaccine-induced acute thrombocytopenic purpura in children. Pediatrics. 2006; 85 (6): 8–12 (in Russ.).
  19. Anaev A.H., Knyazhevskaya N.P. Coagulopathy in COVID-19: focus on anticoagulant therapy. Practical pulmonology. 2020; 1: 3–13 (in Russ.).
  20. Tang N., Li D., Wang X. et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844–7. DOI: 10.1111/jth.14768
  21. Ostovan V.R., Foroughi R., Rostami M. et al. Cerebral venous sinus thrombosis associated with COVID-19: a case series and literature review. J Neurol. 2021; 22: 1–12. DOI: 10.1007/s00415-021-10450-8
  22. Mercado N.B., Zahn R., Wegmann F. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020; 586 (7830): 583–8. DOI: 10.1038/s41586-020-2607
  23. See I., Su J.R., Lale A et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination. J Am Med Assoc. 2021; 325 (24): 2448–56. DOI: 10.1001/jama.2021.7517
  24. Greinacher A., Selleng K., Warkentin T.E. Autoimmune heparine-induced thrombocytopenia. J Thromb Haemost. 2017; 15 (11): 2099–114. DOI: 10.1111/jth.13813
  25. Franchini М., Liumbruno G.M., Pezzo М. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol. 2021; 107 (2): 173–80. DOI: 10.1111/ejh.13665
  26. Lunn М.Р., Cornblath D.R., Jacobs B.C. et al. COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. Brain. 2021; 144 (2): 357–60. DOI: 10.1093/brain/awaa444
  27. Shao S.C., Wang C. H., Chang K.C. Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerg Infect Dis. 2021; 27 (12): 3175–8. DOI: 10.3201/eid2712.211634
  28. Dufour C., Co T.K., Liu A. GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome - A case report, systemic review and implication for vaccine development. Brain. 2021; 12: 100203. DOI: 10.1016/j.bbih.2021.100203
  29. Nassar M., Nso N., Gonzalez C. et al. COVID-19 vaccine-induced myocarditis: Case report with literature review. Diabetes Metab Syndr. 2021; 15 (5): 102205. DOI: 10.1016/j.dsx.2021.102205
  30. Salah H.M., Mehta J.L. COVID-19 Vaccine and Myocarditis. Am J Cardiol. 2021; 157 (15): 146–8. DOI: 10.1016/j.amjcard.2021.07.009
  31. Lazaru J.V., Ratzan S.C., Palayew A. et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021; 27 (2): 225–8. DOI: 10.1038/s41591-020-1124-9
  32. Skjefte M., Ngirbabul M., Akeju O. et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. Eur J Epidemiol. 2021; 36 (2): 197–211. DOI: 10.1007/s10654-021-00728-6
  33. Cobos M.D., Monzon L.L, Bosch-Capblanch X. Exposing concerns about vaccination in low- and middle-income countries: a systematic review. Int J Public Health. 2015; 60 (7): 767–80. DOI: 10.1007/s00038-015-0715-6
  34. Thomson A., Vallee-Tourangeau G., Suggs L.S. Strategies to increase vaccine acceptance and uptake: from behavioral insights to context-specific, culturally-appropriate, evidence-based communications and interventions. Vaccine. 2018; 36: 6457–8. DOI: 10.1016/j.vaccine.2018.08.031